Secondary Malignancies in the Era of High-Precision Radiation Therapy.

Balcer-Kubiczek EK, Eley JG
Crit Rev Oncog. 2018 23 (1-2): 93-112

PMID: 29953369 · DOI:10.1615/CritRevOncog.2018025830

Although modern radiation therapy delivers a localized distribution of ionizing energy that can be used to cure primary cancers for many patients, the inevitable radiation exposure to non-targeted normal tissue leads to a risk of a radiation-related new cancer. Modern therapies often produce a complex spectrum of secondary particles, both charged and uncharged, that must be considered both in their physical radiation transport throughout the patient and their potential to induce biological damage, which depends on the microscopic energy deposition from the cascade of primary, secondary, and downstream particles. This work summarizes the experimental data for relative biological effectiveness for particles associated with modern radiotherapy in light of their capacity to induce secondary malignancies in patients. A distinction is highlighted between the radiobiological experimental data and the coarser metrics used frequently in radiation protection. For critical assessment of the risks of secondary malignancies for patients undergoing radiation therapy, a detailed description of primary and secondary radiation fields is needed, though not routinely considered for individual patient treatments. Furthermore, not only the particle type, but also the microscopic dose and track structure, must be considered, which points to a demand for detailed physics models and high-performance computing strategies to model the risks.

MeSH Terms (10)

Animals Cell Transformation, Neoplastic Humans Neoplasms Neoplasms, Second Primary Precision Medicine Radiation, Ionizing Radiotherapy Radiotherapy Dosage Risk Assessment

Connections (1)

This publication is referenced by other Labnodes entities: